Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice

1998 ◽  
Vol 95 (3) ◽  
pp. 235 ◽  
Author(s):  
Martin G. BUCKLEY ◽  
Neil J. MARCUS ◽  
Magdi H. YACOUB ◽  
Donald R.J. SINGER
Keyword(s):  
Clinical Practice ◽  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Non Invasive

Application of preoperative brain natriuretic peptide levels in clinical practice

Vascular ◽  
2013 ◽  
Vol 21 (4) ◽  
pp. 225-231 ◽  
Author(s):  
Marlin Wayne Causey ◽  
Derek P McVay ◽  
Morohunranti Oguntoye ◽  
Charles Andersen ◽  
Niten Singh
Keyword(s):  
Clinical Practice ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Multivariable Analysis ◽  
Arterial Disease ◽  
Cardiac Complications ◽  
Postoperative Risk ◽  
Receiver Operator Curve Analysis ◽  
Artery Disease ◽  
Peripheral Arterial

The purpose of the study was to determine the clinical utility and practical application of preoperative brain natriuretic peptide (BNP) levels. This is a retrospective review of operating room procedures from November 2006 to March 2009. Preoperative history and physical were reviewed and BNP laboratory levels obtained prior to all procedures and the postoperative course reviewed for incidence of 30-day cardiac complications. A receiver operator curve analysis demonstrated that a preoperative BNP threshold ≥95.5 pg/mL correctly identified 75% of patients with cardiac complications and values ≤18.5 pg/mL identified 100% of patients without adverse postoperative cardiac complications. Multivariable analysis also revealed a history of peripheral arterial disease as the most significant preoperative predictor of cardiac complications followed by BNP above the threshold (odds ratio = 3.7), hypothyroidism, coronary artery disease and prior myocardial infarction. In conclusion, preoperative BNP levels are a useful adjunct in clinical practice to help identify those patients with a high postoperative risk and those with a minimal postoperative risk.

BRAIN NATRIURETIC PEPTIDE AS A MARKER OF CARDIAC FUNCTION AFTER ULTRAENDURANCE EXERCISE 700

1996 ◽  
Vol 28 (Supplement) ◽  
pp. 117
Author(s):  
T. Shimomitsu ◽  
H. Iwane ◽  
Y. Odagiri ◽  
T. Katsumura ◽  
T. Hamaoka ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide

Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction

1999 ◽  
Vol 97 (3) ◽  
pp. 255-258 ◽  
Author(s):  
P. F. DOWNIE ◽  
S. TALWAR ◽  
I. B. SQUIRE ◽  
J. E. DAVIES ◽  
D. B. BARNETT ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Left Ventricular Dysfunction ◽  
Room Temperature ◽  
Ventricular Dysfunction ◽  
Plasma Concentrations ◽  
Left Ventricular ◽  
Blood Samples ◽  
The Stability

Plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) are raised in patients with left ventricular dysfunction. Measurement of this peptide has a potential diagnostic role in the identification and assessment of patients with heart failure. The stability of this peptide over time periods and conditions pertaining to routine clinical practice has not been reported previously. Blood samples were obtained from 15 subjects. One aliquot was processed immediately, and the remaining portions of the blood samples were stored for 24 h or 48 h at room temperature or on ice prior to processing. Plasma concentrations of NT-proBNP were measured with a novel immunoluminometric assay developed within our laboratory. Mean plasma concentrations of NT-proBNP were not significantly different whether blood samples were centrifuged immediately and stored at -70 °C or kept at room temperature or on ice for 24 h or 48 h. The mean percentage differences from baseline (reference standard) were +5.2% (95% confidence interval +18.2 to -7.8%) and +0.8% (+15.2 to -13.7%) after storage for 24 h at room temperature or on ice respectively, and +8.9% (+24.2 to -6.5%) and +3.2% (+15.1 to -0.9%) for storage for 48 h at room temperature or on ice respectively. Pearson correlation coefficients for baseline NT-proBNP concentrations compared with levels at 48 h at room temperature or on ice were r = 0.89 and r = 0.83 respectively (both P < 0.0001). Thus NT-proBNP extracted from plasma samples treated with EDTA and aprotinin is stable under conditions relevant to clinical practice.

scholarly journals Circulating N-terminal brain natriuretic peptide and cardiac function in response to acute systemic hypoxia in healthy humans

2014 ◽  
Vol 12 (1) ◽  
pp. 189 ◽  
Author(s):  
Ilkka Heinonen ◽  
Matti Luotolahti ◽  
Olli Vuolteenaho ◽  
Mikko Nikinmaa ◽  
Antti Saraste ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Healthy Humans ◽  
Systemic Hypoxia

scholarly journals Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice

Heart ◽  
1997 ◽  
Vol 78 (6) ◽  
pp. 594-597 ◽  
Author(s):  
D. R Murdoch ◽  
J. Byrne ◽  
J. J Morton ◽  
T. A McDonagh ◽  
S. D Robb ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Whole Blood ◽  
Rapid Assay

Brain Natriuretic Peptide in Hemodialysis Patients: Predictive Value for Hemodynamic Change during Hemodialysis and Cardiac Function

2007 ◽  
Vol 28 (1) ◽  
pp. 122-127 ◽  
Author(s):  
Tetsutaro Matayoshi ◽  
Toako Kato ◽  
Hajime Nakahama ◽  
Hiroto Nakata ◽  
Fumiki Yoshihara ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Predictive Value ◽  
Hemodialysis Patients ◽  
Hemodynamic Change

scholarly journals Measurement of Cardiac Natriuretic Hormones (Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Related Peptides) in Clinical Practice: The Need for a New Generation of Immunoassay Methods

2000 ◽  
Vol 46 (10) ◽  
pp. 1529-1534 ◽  
Author(s):  
Aldo Clerico ◽  
Silvia Del Ry ◽  
Daniela Giannessi
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
Atrial Natriuretic Peptide ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Sensitivity And Specificity ◽  
Natriuretic Peptides ◽  
Healthy Subjects ◽  
Cardiac Natriuretic Peptides ◽  
New Generation

Abstract Background: Cardiac natriuretic hormones (CNHs) are a family of related peptides, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and other peptides derived from the N-terminal portion of the proANP and proBNP peptide chains. Assays for cardiac natriuretic peptides have been proposed to help assess clinical conditions associated with expanded fluid volume. In particular, the assays can be useful for distinguishing healthy subjects from patients in different stages of heart failure. Measurements of these hormones have also been considered for prognostic indicators of long-term survival in patients with heart failure and/or after acute myocardial infarction. The different CNHs differ in their production/secretion patterns and have different clearance rates. Furthermore, there are numerous proposed assay configurations for each of these hormones, and it is not clear which assay provides the best pathophysiological and/or clinical information. Approach: Here we review recent studies concerning the competitive (such as RIA, enzyme immunoassay, or luminescence immunoassay) and noncompetitive immunoassays (such as two-site IRMA, ELISA, or immunoluminometric assay) for the different cardiac natriuretic peptides to compare the analytical characteristics and clinical relevance of assays for the different CNHs and the different assay formats. Content: Developing sensitive, precise, and accurate immunoassays for cardiac natriuretic peptides has been difficult because of their low concentrations (on average, ∼3–6 pmol/L) in healthy subjects and because of their structural, metabolic, and physiological characteristics. Competitive assays have historically suffered from lack of sensitivity and specificity for the biologically active peptides. These usually require tedious extraction procedures prior to analysis. Recently, immunometric assays have been developed that have improved sensitivity and specificity; it appears these will be the methods of choice. Summary: To date, there is no consensus on the best assay procedure of cardiac natriuretic peptides. To facilitate widespread propagation of determination of these hormones in routine clinical practice, it will be necessary to study the new generation of noncompetitive immunometric methods that are less time-consuming and more sensitive and specific. Although several studies suggest that BNP exhibits better clinical utility than the other CNHs, more studies examining multiple CNHs in the same cohorts of patients will be necessary.

Sign in / Sign up

Export Citation Format

Share Document